These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Study on the role of angiogenesis and related factors in leukemias]. Zhang Y; Gu J; Wang M; Ma L; Wang XL; He B; Sun M Zhonghua Xue Ye Xue Za Zhi; 2005 Mar; 26(3):175-8. PubMed ID: 15946533 [TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Ries C; Loher F; Zang C; Ismair MG; Petrides PE Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746 [TBL] [Abstract][Full Text] [Related]
5. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Janowska-Wieczorek A; Majka M; Marquez-Curtis L; Wertheim JA; Turner AR; Ratajczak MZ Leukemia; 2002 Jun; 16(6):1160-6. PubMed ID: 12040448 [TBL] [Abstract][Full Text] [Related]
6. Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. Sillaber C; Mayerhofer M; Aichberger KJ; Krauth MT; Valent P Eur J Clin Invest; 2004 Aug; 34 Suppl 2():2-11. PubMed ID: 15291801 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia. Zhelyazkova AG; Tonchev AB; Kolova P; Ivanova L; Gercheva L Scand J Clin Lab Invest; 2008; 68(6):492-500. PubMed ID: 18609087 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. Krauth MT; Simonitsch I; Aichberger KJ; Mayerhofer M; Sperr WR; Sillaber C; Schneeweiss B; Mann G; Gadner H; Valent P Am J Clin Pathol; 2004 Apr; 121(4):473-81. PubMed ID: 15080298 [TBL] [Abstract][Full Text] [Related]
9. [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia]. Zheng SE; Jin J; Tong XM; Qian WB; Xue YQ Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):920-3. PubMed ID: 17533744 [TBL] [Abstract][Full Text] [Related]
10. Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia. Litwin C; Leong KG; Zapf R; Sutherland H; Naiman SC; Karsan A Am J Hematol; 2002 May; 70(1):22-30. PubMed ID: 11994978 [TBL] [Abstract][Full Text] [Related]
11. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Zhou HJ; Wang WQ; Wu GD; Lee J; Li A Vascul Pharmacol; 2007; 47(2-3):131-8. PubMed ID: 17581794 [TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Xiao Z; Wang Y; Lu L; Li Z; Peng Z; Han Z; Hao Y Leuk Res; 2006 Jan; 30(1):54-9. PubMed ID: 15982734 [TBL] [Abstract][Full Text] [Related]
13. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Bellamy WT; Richter L; Frutiger Y; Grogan TM Cancer Res; 1999 Feb; 59(3):728-33. PubMed ID: 9973224 [TBL] [Abstract][Full Text] [Related]
14. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. Kim MH J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886 [TBL] [Abstract][Full Text] [Related]
15. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients. Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Dalal S; Berry AM; Cullinane CJ; Mangham DC; Grimer R; Lewis IJ; Johnston C; Laurence V; Burchill SA Clin Cancer Res; 2005 Mar; 11(6):2364-78. PubMed ID: 15788688 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Samaniego F; Markham PD; Gendelman R; Watanabe Y; Kao V; Kowalski K; Sonnabend JA; Pintus A; Gallo RC; Ensoli B Am J Pathol; 1998 Jun; 152(6):1433-43. PubMed ID: 9626048 [TBL] [Abstract][Full Text] [Related]
18. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244 [TBL] [Abstract][Full Text] [Related]
19. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Hou HA; Chou WC; Lin LI; Tang JL; Tseng MH; Huang CF; Yao M; Chen CY; Tsay W; Tien HF Leuk Res; 2008 Jun; 32(6):904-12. PubMed ID: 17904634 [TBL] [Abstract][Full Text] [Related]
20. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. Ma X; Ottino P; Bazan HE; Bazan NG Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2915-21. PubMed ID: 15326102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]